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We thank comments from Dr. Ayçiçek et al. [1] on our previous manuscript [2] that 
provided an opportunity to discuss this interesting topic.  
First of all, we would like to remind that we are focusing on ‘disabling 
dementia’, not clinical diagnosed dementia. The concept of disabling dementia aims to 
prevent any type of dementia that brings disabling. It is especially important to 
remember that, from public health point of view, preventing whichever subtypes of 
dementia should be remarked. We agree that clarifying etiology of each type of 
dementia is of interest, and showed the results for cases with history of stroke, and those 
without stroke as supplemental analysis. Our study, however, did not aim to clarify 
which type of dementia could be prevented by α-linolenic acid. 
As for residual confounding, we do not have data on depression, head trauma, 
low vitamin B12 levels and thyroid functions. However, we do not believe these would 
impact the results materially, because the prevalence of these factors were likely to be 
very few in the general Japanese population, and these were unlikely to correlate with 
serum α-linolenic acid levels.  
Dr. Ayçiçek et al. also concerned the reliability of disabling dementia 
diagnoses. We are sure that diagnoses based on NIA-AA or DSM-V criteria should be 
more precise to identify definite dementia cases in clinical settings, but to apply these 
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criteria to a number of participants in general settings is unrealistic due to time, cost and 
personnel. Using information from the National Long-term Care Insurance System, a 
compulsory insurance system of Japan, is one of the practical ways to keep 
completeness of surveillance, which should have higher priority from epidemiological 
point of view. We have compared our epidemiological diagnosis with diagnosis by 
psychiatrists and confirmed that the sensitivity and specificity of our diagnoses were 
83% and 96%, respectively. (Noda H, et al. in submitting) 
We agree that it is uncertain when dementia starts exactly in the life course. We 
used a strategy of constructing the baseline surveys at least 5 years before the dementia 
diagnosis to exclude overt dementia at baseline, but we agree that this strategy is not 
enough to exclude preclinical dementia. 
True single measurement of α-linolenic acid levels could be a drawback of this 
study, but measuring serial measurements over 25 years for more than 7500 people is 
costly and not practical. This is why we chose the nested case-control design. We have 
confirmed a good repeatability of serum α-linolenic acid during 8 years as discussed in 
the paper [2], and thus we consider that single measurement did not largely dilute the 
association. As we concluded in the paper [2], the causality needs to be confirmed by 
randomized control trials. 
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